Published in Clin Cancer Res on August 01, 2005
64Cu-labeled alpha-melanocyte-stimulating hormone analog for microPET imaging of melanocortin 1 receptor expression. Bioconjug Chem (2007) 1.79
111In-labeled lactam bridge-cyclized alpha-melanocyte stimulating hormone peptide analogues for melanoma imaging. Bioconjug Chem (2008) 1.48
Metastatic melanoma imaging with an (111)In-labeled lactam bridge-cyclized alpha-melanocyte-stimulating hormone peptide. Nucl Med Biol (2009) 1.36
Phage display in molecular imaging and diagnosis of cancer. Chem Rev (2010) 1.34
Reduction of the ring size of radiolabeled lactam bridge-cyclized alpha-MSH peptide, resulting in enhanced melanoma uptake. J Nucl Med (2010) 1.24
203Pb-labeled alpha-melanocyte-stimulating hormone peptide as an imaging probe for melanoma detection. J Nucl Med (2008) 1.22
Small-animal PET of melanocortin 1 receptor expression using a 18F-labeled alpha-melanocyte-stimulating hormone analog. J Nucl Med (2007) 1.16
Effects of the amino acid linkers on the melanoma-targeting and pharmacokinetic properties of 111In-labeled lactam bridge-cyclized alpha-MSH peptides. J Nucl Med (2011) 1.14
Effect of DOTA position on melanoma targeting and pharmacokinetic properties of 111In-labeled lactam bridge-cyclized alpha-melanocyte stimulating hormone peptide. Bioconjug Chem (2009) 1.10
Towards translation of 212Pb as a clinical therapeutic; getting the lead in! Dalton Trans (2011) 1.09
Evaluation of a novel Arg-Gly-Asp-conjugated α-melanocyte stimulating hormone hybrid peptide for potential melanoma therapy. Bioconjug Chem (2009) 1.08
Gallium-67-labeled lactam bridge-cyclized alpha-melanocyte stimulating hormone peptide for primary and metastatic melanoma imaging. Bioconjug Chem (2009) 1.06
Melanoma targeting with alpha-melanocyte stimulating hormone analogs labeled with fac-[99mTc(CO)3]+: effect of cyclization on tumor-seeking properties. J Biol Inorg Chem (2008) 1.02
Targeted alpha-therapy: past, present, future? Dalton Trans (2007) 1.01
Efficient bifunctional decadentate ligand 3p-C-DEPA for targeted α-radioimmunotherapy applications. Bioconjug Chem (2011) 0.99
Design and evaluation of new Tc-99m-labeled lactam bridge-cyclized alpha-MSH peptides for melanoma imaging. Mol Pharm (2013) 0.95
Peptide-targeted radionuclide therapy for melanoma. Crit Rev Oncol Hematol (2008) 0.93
Cu-64-labeled lactam bridge-cyclized α-MSH peptides for PET imaging of melanoma. Mol Pharm (2012) 0.92
Synthesis and iron sequestration equilibria of novel exocyclic 3-hydroxy-2-pyridinone donor group siderophore mimics. Inorg Chem (2010) 0.91
Replacement of the Lys linker with an Arg linker resulting in improved melanoma uptake and reduced renal uptake of Tc-99m-labeled Arg-Gly-Asp-conjugated alpha-melanocyte stimulating hormone hybrid peptide. Bioorg Med Chem (2010) 0.91
Gallium-67-labeled lactam bridge-cyclized alpha-MSH peptides with enhanced melanoma uptake and reduced renal uptake. Bioconjug Chem (2012) 0.90
Fluorescent imaging of cancerous tissues for targeted surgery. Adv Drug Deliv Rev (2014) 0.90
Differential Antitumor Effects of IgG and IgM Monoclonal Antibodies and Their Synthetic Complementarity-Determining Regions Directed to New Targets of B16F10-Nex2 Melanoma Cells. Transl Oncol (2010) 0.87
Melanoma imaging using (111)In-, (86)Y- and (68)Ga-labeled CHX-A''-Re(Arg11)CCMSH. Nucl Med Biol (2009) 0.83
Targeted melanoma imaging and therapy with radiolabeled alpha-melanocyte stimulating hormone peptide analogues. G Ital Dermatol Venereol (2010) 0.82
Malignant melanoma and melanocortin 1 receptor. Biochemistry (Mosc) (2013) 0.81
Melanoma targeting property of a Lu-177-labeled lactam bridge-cyclized alpha-MSH peptide. Bioorg Med Chem Lett (2013) 0.79
Anatomical and molecular imaging of skin cancer. Clin Cosmet Investig Dermatol (2008) 0.77
The synthetic parasite-derived peptide GK1 increases survival in a preclinical mouse melanoma model. Cancer Biother Radiopharm (2013) 0.77
Search of ligands suitable for (212)Pb/(212)Bi in vivo generators. J Radioanal Nucl Chem (2012) 0.76
Structural modification on the Lys linker enhanced tumor to kidney uptake ratios of 99mTc-labeled RGD-conjugated α-MSH hybrid peptides. Mol Pharm (2012) 0.76
Tc-99m-labeled RGD-conjugated alpha-melanocyte stimulating hormone hybrid peptides with reduced renal uptake. Amino Acids (2015) 0.75
Population diversity and the portfolio effect in an exploited species. Nature (2010) 6.88
Biocomplexity and fisheries sustainability. Proc Natl Acad Sci U S A (2003) 5.01
microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide. J Nucl Med (2005) 2.96
Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. Cancer Res (2003) 1.97
Evidence for geomagnetic imprinting as a homing mechanism in Pacific salmon. Curr Biol (2013) 1.93
High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res (2006) 1.82
99mTc- and 111In-labeled alpha-melanocyte-stimulating hormone peptides as imaging probes for primary and pulmonary metastatic melanoma detection. J Nucl Med (2007) 1.81
Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. J Nucl Med (2003) 1.76
Eco-evolutionary vs. habitat contributions to invasion in salmon: experimental evaluation in the wild. Mol Ecol (2007) 1.61
MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med (2010) 1.61
Evaluation of the human melanoma targeting properties of radiolabeled alpha-melanocyte stimulating hormone peptide analogues. Bioconjug Chem (2003) 1.58
An evaluation of the effects of conservation and fishery enhancement hatcheries on wild populations of salmon. Adv Mar Biol (2007) 1.54
Imaging of melanoma using 64Cu- and 86Y-DOTA-ReCCMSH(Arg11), a cyclized peptide analogue of alpha-MSH. J Med Chem (2005) 1.49
111In-labeled lactam bridge-cyclized alpha-melanocyte stimulating hormone peptide analogues for melanoma imaging. Bioconjug Chem (2008) 1.48
Synthesis and biologic evaluation of 64Cu-labeled rhenium-cyclized alpha-MSH peptide analog using a cross-bridged cyclam chelator. J Nucl Med (2007) 1.42
Therapeutic efficacy of a 188Re-labeled alpha-melanocyte-stimulating hormone peptide analog in murine and human melanoma-bearing mouse models. J Nucl Med (2005) 1.41
In vivo evaluation of 188Re-labeled alpha-melanocyte stimulating hormone peptide analogs for melanoma therapy. Int J Cancer (2002) 1.37
High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol (2007) 1.31
MDA-MB-435 human breast carcinoma cell homo- and heterotypic adhesion under flow conditions is mediated in part by Thomsen-Friedenreich antigen-galectin-3 interactions. J Biol Chem (2002) 1.28
Copper transport into the secretory pathway is regulated by oxygen in macrophages. J Cell Sci (2009) 1.24
Improved viability of populations with diverse life-history portfolios. Biol Lett (2009) 1.24
Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts. Blood (2002) 1.23
203Pb-labeled alpha-melanocyte-stimulating hormone peptide as an imaging probe for melanoma detection. J Nucl Med (2008) 1.22
In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy. J Nucl Med (2003) 1.22
Modification of the structure of a metallopeptide: synthesis and biological evaluation of (111)In-labeled DOTA-conjugated rhenium-cyclized alpha-MSH analogues. J Med Chem (2002) 1.21
Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model. Cancer Res (2010) 1.19
Evaluation of beta-absorbed fractions in a mouse model for 90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu radionuclides. Cancer Biother Radiopharm (2005) 1.18
Reproductive success of captively bred and naturally spawned Chinook salmon colonizing newly accessible habitat. Evol Appl (2012) 1.15
Does variation in selection imposed by bears drive divergence among populations in the size and shape of sockeye salmon? Evolution (2009) 1.12
Predation by bears drives senescence in natural populations of salmon. PLoS One (2007) 1.12
Tumor-targeting properties of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues in a murine melanoma model. Nucl Med Biol (2005) 1.12
TLD assessment of mouse dosimetry during microCT imaging. Med Phys (2008) 1.11
Ten years of varying lake level and selection on size-at-maturity in sockeye salmon. Ecology (2007) 1.08
Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211. Cancer Res (2009) 1.08
Radioiodination of rhenium cyclized alpha-melanocyte-stimulating hormone resulting in enhanced radioactivity localization and retention in melanoma. Cancer Res (2004) 1.04
Continuous real time ex vivo epifluorescent video microscopy for the study of metastatic cancer cell interactions with microvascular endothelium. Clin Exp Metastasis (2003) 1.02
Early marine migration patterns of wild coastal cutthroat trout (Oncorhynchus clarki clarki), steelhead trout (Oncorhynchus mykiss), and their hybrids. PLoS One (2010) 1.02
Reducing renal uptake of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues. Nucl Med Biol (2006) 1.01
Therapeutic efficacy of a 177Lu-labeled DOTA conjugated alpha-melanocyte-stimulating hormone peptide in a murine melanoma-bearing mouse model. Cancer Biother Radiopharm (2007) 1.00
Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. J Nucl Med (2005) 1.00
Evaluation of an 111In-radiolabeled peptide as a targeting and imaging agent for ErbB-2 receptor expressing breast carcinomas. Clin Cancer Res (2007) 0.99
Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates. Blood (2009) 0.99
Selective T-cell ablation with bismuth-213-labeled anti-TCRalphabeta as nonmyeloablative conditioning for allogeneic canine marrow transplantation. Blood (2003) 0.98
Overexpression of the RNA binding protein HuR impairs tumor growth in triple negative breast cancer associated with deficient angiogenesis. Cell Cycle (2010) 0.98
Identification and characterization of peptides that bind human ErbB-2 selected from a bacteriophage display library. J Protein Chem (2002) 0.97
Gallium-68-labeled DOTA-rhenium-cyclized alpha-melanocyte-stimulating hormone analog for imaging of malignant melanoma. Nucl Med Biol (2007) 0.97
MIRD commentary: proposed name for a dosimetry unit applicable to deterministic biological effects--the barendsen (Bd). J Nucl Med (2009) 0.97
Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9. Clin Cancer Res (2009) 0.94
A quantitative volumetric micro-computed tomography method to analyze lung tumors in genetically engineered mouse models. Neoplasia (2009) 0.94
Role of genetic background in determining phenotypic severity throughout postnatal development and at peak bone mass in Col1a2 deficient mice (oim). Bone (2008) 0.94
Acyclic chelate with ideal properties for (68)Ga PET imaging agent elaboration. J Am Chem Soc (2010) 0.93
Thomsen-Friedenreich and Tn antigens in nipple fluid: carbohydrate biomarkers for breast cancer detection. Clin Cancer Res (2005) 0.93
Peptide-targeted radionuclide therapy for melanoma. Crit Rev Oncol Hematol (2008) 0.93
Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia. Cancer Res (2009) 0.91
Evaluation of combined (177)Lu-DOTA-8-AOC-BBN (7-14)NH(2) GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice. Cancer Biother Radiopharm (2006) 0.90
Gadolinium-153 as a brachytherapy isotope. Phys Med Biol (2013) 0.90
Melanoma imaging with pretargeted bivalent bacteriophage. J Nucl Med (2007) 0.90
Cycles, stochasticity and density dependence in pink salmon population dynamics. Proc Biol Sci (2010) 0.90
High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes. J Nucl Med (2004) 0.90
90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma. J Nucl Med (2003) 0.89
MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy. J Nucl Med (2015) 0.89
Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model. Blood (2011) 0.89
Single nucleotide polymorphisms unravel hierarchical divergence and signatures of selection among Alaskan sockeye salmon (Oncorhynchus nerka) populations. BMC Evol Biol (2011) 0.89
Development of high-specific-activity (68)Ga-labeled DOTA-rhenium-cyclized alpha-MSH peptide analog to target MC1 receptors overexpressed by melanoma tumors. Nucl Med Biol (2009) 0.88
Natural habitat change, commercial fishing, climate, and dispersal interact to restructure an Alaskan fish metacommunity. Oecologia (2009) 0.88
A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies. Cancer Res (2013) 0.88
Carbohydrate antigens in nipple aspirate fluid predict the presence of atypia and cancer in women requiring diagnostic breast biopsy. BMC Cancer (2010) 0.86
MIRD pamphlet No. 24: Guidelines for quantitative 131I SPECT in dosimetry applications. J Nucl Med (2013) 0.86
Pm-149 DOTA bombesin analogs for potential radiotherapy. in vivo comparison with Sm-153 and Lu-177 labeled DO3A-amide-betaAla-BBN(7-14)NH(2). Nucl Med Biol (2002) 0.85
Can interbreeding of wild and artificially propagated animals be prevented by using broodstock selected for a divergent life history? Evol Appl (2012) 0.85
Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma. Clin Cancer Res (2011) 0.84
Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-biotin. Clin Cancer Res (2004) 0.84
Multiple-estimate monte carlo calculation of the dose rate constant for a cesium-131 interstitial brachytherapy seed. Med Phys (2007) 0.84
Biodistribution of yttrium-90-labeled anti-CD45 antibody in a nonhuman primate model. Clin Cancer Res (2005) 0.83
Bifunctional phage-based pretargeted imaging of human prostate carcinoma. Nucl Med Biol (2009) 0.83
Alpha-melanocyte stimulating hormone peptide-targeted melanoma imaging. Front Biosci (2007) 0.83
In vitro and in vivo evaluation of ⁶⁴Cu-radiolabeled KCCYSL peptides for targeting epidermal growth factor receptor-2 in breast carcinomas. Cancer Biother Radiopharm (2010) 0.83
Melanoma imaging using (111)In-, (86)Y- and (68)Ga-labeled CHX-A''-Re(Arg11)CCMSH. Nucl Med Biol (2009) 0.83
Combinatorial evolution of high-affinity peptides that bind to the Thomsen-Friedenreich carcinoma antigen. J Protein Chem (2003) 0.83
Size selectivity of predation by brown bears depends on the density of their sockeye salmon prey. Am Nat (2013) 0.83
Alpha-melanocyte-stimulating hormone peptide analogs labeled with technetium-99m and indium-111 for malignant melanoma targeting. Cancer (2002) 0.82
Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model. Blood (2013) 0.81
First in vivo evaluation of liposome-encapsulated 223Ra as a potential alpha-particle-emitting cancer therapeutic agent. Anticancer Res (2006) 0.81
Production of high-purity radium-223 from legacy actinium-beryllium neutron sources. Curr Radiopharm (2012) 0.80
Evaluation of hydroxyurea-induced fetal skeletal changes in Dutch belted rabbits by micro-computed tomography and alizarin red staining. Birth Defects Res B Dev Reprod Toxicol (2009) 0.80
Micro-computed tomography and alizarin red evaluations of boric acid-induced fetal skeletal changes in Sprague-Dawley rats. Birth Defects Res B Dev Reprod Toxicol (2009) 0.80
Preparation and biological evaluation of 111In-, 177Lu- and 90Y-labeled DOTA analogues conjugated to B72.3. Nucl Med Biol (2007) 0.80
Thermal heterogeneity mediates the effects of pulsed subsidies across a landscape. Ecology (2010) 0.79